Oxidosqualene Cyclase (OSC) Inhibitors for the Treatment of Dyslipidemia
DOI:
https://doi.org/10.2533/000942905777676858Keywords:
Dyslipidemia, Medicinal chemistry, Oxidosqualene cyclase, Structure-activity relationshipAbstract
Novel inhibitors of oxidosqualene cyclase (OSC) for the treatment of dyslipidemia are reported. Starting point for the chemistry program was a set of compounds derived from a fungicide project which, in addition to high affinity for OSC from Candida albicans, also showed high affinity for the human enzyme (hOSC). Here the evaluation process of different scaffolds is outlined for two representative series, the phenyl substituted benzo[d]isothiazoles and the aminocyclohexanes. The most promising compounds derived from the latter series were further profiled in vivo and showed promising properties with respect to modulation of lipid parameters.Downloads
Published
2005-03-01
Issue
Section
Scientific Articles
License
Copyright (c) 2005 Swiss Chemical Society
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
[1]
H. Dehmlow, R. Thoma, A. Ruf, N. Panday, E. Von Der Mark, O. Morand, H. P. Märki, M. Kansy, P. Hartman, P. Coassolo, A. Chucholowski, D. Blum-Kaelin, J. Aebi, J. Ackermann, T. Schulz-Gasch, Chimia 2005, 59, 72, DOI: 10.2533/000942905777676858.